Signet-Ring Cell Carcinoma of the Colon: An Educational Overview

What it is and where it sits in current classification

Signet-ring cell carcinoma is a recognized histologic subtype of colorectal adenocarcinoma in the current (fifth edition) WHO classification of digestive system tumours [1]. It is defined by a distinctive cytology rather than by a particular anatomic location: tumour cells accumulate abundant intracytoplasmic mucin that pushes the nucleus to one side, producing the characteristic "signet-ring" appearance under the microscope.

The essential quantitative threshold is that more than 50% of the tumour must be composed of signet-ring cells for the diagnosis to be applied [1]. The 50% threshold is a biological statement, not a bookkeeping one: it carries prognostic and biological weight. When signet-ring cells are present but constitute less than that majority, the tumour is generally classified within another category (for example, as an adenocarcinoma with signet-ring cell features), with the signet-ring component noted. The 50% rule therefore functions as a reproducible dividing line intended to identify tumours whose behavior is dominated by this morphology.

To state it plainly: signet-ring cell carcinoma remains a recognized subtype in the current classification, it has not been removed, merged into an umbrella category, or introduced as a wholly new entity. It persists as a distinct, named subtype because its defining morphology is reproducible and its associations consistently adverse.

How a pathologist recognizes it: morphology → IHC → molecular

Diagnosis proceeds in a deliberate order, beginning with what can be seen on routine stained sections and moving to ancillary tests only as needed to resolve specific questions.

Morphology (first). The diagnosis is fundamentally morphologic. The pathologist identifies tumour cells with a globule of intracytoplasmic mucin that displaces and compresses the nucleus against the cell membrane. To qualify as signet-ring cell carcinoma, these cells must make up more than half of the neoplasm [1]. Signet-ring cells may lie within pools of extracellular mucin or infiltrate singly through the stroma; both patterns count toward the diagnosis so long as the cytology is that of the signet-ring cell. By definition this is a high-grade tumour, so the recognition of the morphology simultaneously establishes the grade (discussed below).

Immunohistochemistry (second). IHC is used chiefly to confirm the origin of the tumour and, importantly, to help exclude mimics, not to make the morphologic diagnosis itself. The immunophenotype of colonic signet-ring cell carcinoma is variable: CK20 and CDX2 expression may be present but are not reliably retained, and CDX2 in particular can be lost [1]. CDX2 is otherwise a sensitive marker of intestinal-origin adenocarcinoma [2], so its attenuation in a poorly differentiated colonic tumour is a recognized pitfall; SATB2 combined with CK20 is a more durable colorectal lineage signature when CDX2 weakens [3]. This variability is a diagnostic pitfall, because a colorectal primary that has lost its usual lineage markers can superficially resemble a metastasis from elsewhere. E-cadherin may be reduced in some cases [1], a finding that overlaps with tumours of other origins (notably lobular carcinoma of the breast) and therefore must be interpreted within the full clinical and immunohistochemical context rather than in isolation.

The single most important practical use of IHC and clinical correlation is to exclude metastatic signet-ring carcinoma from other sites, particularly gastric signet-ring cell carcinoma and lobular carcinoma of the breast, both of which can present in or spread to the bowel and mimic a colonic primary [1]. Because the colonic immunophenotype is itself variable, no single stain settles the question; the pathologist integrates the panel with the clinical history, imaging, and endoscopic findings.

Molecular (third). Molecular characterization further refines the picture. A subset of signet-ring cell carcinomas is microsatellite instability, high (MSI-H), while a distinct microsatellite-stable (MSS) subset behaves aggressively [1]. This molecular dichotomy is clinically meaningful because microsatellite status carries implications for prognosis and for eligibility for particular therapeutic classes: MSI-high colorectal cancer carries a more favourable prognosis and does not derive benefit from single-agent fluoropyrimidine adjuvant therapy [4], and mismatch-repair deficiency defines the group that responds to PD-1, directed immune-checkpoint blockade [5], including in the first-line metastatic setting [6]. Molecular testing is therefore best understood as building on the morphologic diagnosis rather than replacing it.

Grading and classification

Grading in this entity is straightforward: signet-ring cell carcinoma is high-grade by definition [1]. Unlike conventional colorectal adenocarcinoma, where grade is assigned according to the proportion of gland formation, the signet-ring cell subtype does not require separate grading, its recognition automatically places it in the high-grade category. This convention reflects the observation that the signet-ring morphology, when it dominates a tumour, is itself a marker of adverse biology.

Why the distinction matters clinically

Several threads make the accurate recognition of signet-ring cell carcinoma clinically important.

First, it is a marker of adverse morphology [1]. Identifying and correctly classifying a tumour as signet-ring cell carcinoma communicates prognostically relevant information to the treating team, and the high-grade designation follows automatically from the diagnosis; in colorectal cancer more broadly, poor differentiation and adverse histology are established predictors of nodal risk and worse outcome [7,8].

Second, the exclusion of mimics has direct consequences for patient care. A metastatic gastric signet-ring cell carcinoma or a metastatic lobular breast carcinoma involving the colon is a fundamentally different clinical problem from a colonic primary, with different implications for staging and management [1]. Because the colonic immunophenotype is variable, CDX2 may be lost, E-cadherin may be reduced, the pathologist must lean on clinical and immunohistochemical context together to avoid misattributing the tumour's origin.

Third, the molecular subtyping into MSI-H and aggressive MSS groups is relevant to determining eligibility for particular drug classes and to prognostication [1]. This should be understood strictly as an educational statement about how diagnostic findings map to categories of therapy; it is not treatment advice, and decisions about any individual patient's management rest with the clinical team.

Taken together, the diagnostic workflow for signet-ring cell carcinoma illustrates a general principle in surgical pathology: morphology establishes the diagnosis and grade, immunohistochemistry confirms lineage and excludes mimics, and molecular testing stratifies biology and informs downstream eligibility considerations. Each layer answers a different question, and the sequence matters.

References

1. WHO Classification of Tumours Editorial Board. Digestive System Tumours, 5th ed. Lyon: IARC; 2019. ISBN 978-92-832-4499-8.
2. Werling RW, Yaziji H, Bacchi CE, Gown AM. CDX2, a sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol. 2003;27(3):303, 310. PMID: 12604886.
3. Magnusson K, de Wit M, Brennan DJ, et al. SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas. Am J Surg Pathol. 2011;35(7):937, 948. PMID: 21677534.
4. Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28(20):3219, 3226. PMID: 20498393.
5. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409, 413. PMID: 28596308.
6. André T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207, 2218. PMID: 33264544.
7. Brown IS, Bettington ML, Bettington A, et al. Adverse histological features in malignant colorectal polyps: a contemporary series of 239 cases. J Clin Pathol. 2016;69(4):292, 299. PMID: 26424814.
8. Bosch SL, Teerenstra S, de Wilt JH, Cunningham C, Nagtegaal ID. Predicting lymph node metastasis in pT1 colorectal cancer: a systematic review of risk factors providing rationale for therapy decisions. Endoscopy. 2013;45(10):827, 834. PMID: 23884793.